Baili Tianheng announced that the company's self-developed drug marketing application for locally advanced or metastatic non-squamous non-small cell lung cancer with EGFR-sensitive mutations that have previously failed to be treated with EGFR-TKI was officially accepted by the CDE. This application is based on the results of the mid-phase III clinical trial. The study reached the main end point of progression-free survival in the pre-set mid-phase analysis.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.